

## Discovery Laboratories

[View the current Discovery Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/516-Discovery+Laboratories.html)

(<http://www.bioportfolio.com/bi corporate/516-Discovery+Laboratories.html>)

### Contact Details:

**2600 Kelly Road, Suite 100**

**Warrington**

**PA**

**18976-3622**

**United States of America**

Tel: 215.488.9300

Fax: 215.488.9301

Email: [ir@discoverylabs.com](mailto:ir@discoverylabs.com)

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging its platform technology in humanized lung surfactants to develop novel respiratory therapies and pulmonary drug delivery products. Surfactants are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen. Our humanized surfactant technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Surfaxin®, our lead product, is currently in Phase 3 clinical trials for Respiratory Distress Syndrome in premature infants (RDS), a Phase 3 clinical trial for Meconium Aspiration Syndrome in full-term infants (MAS), and a Phase 2 clinical trial for Acute Lung Injury/Acute Respiratory Distress Syndrome in adults (ALI/ARDS).

We are also developing aerosolized formulations of our humanized surfactant to treat respiratory conditions such as asthma and as a novel pulmonary drug delivery vehicle to render drugs more effective when delivered to or via the respiratory tract.

A lack of functional surfactant is associated with several severe respiratory diseases. Research has established that surfactant replacement is highly effective in treating RDS and holds great promise in treating MAS, ALI/ARDS, asthma and other respiratory disorders. However, RDS is the only respiratory disease being treated today with approved surfactants, which are principally animal derived. The current supply of these surfactants is limited and their manufacture is both inexact and expensive, making it difficult to develop these products to treat broader populations for RDS therapy or other respiratory diseases.

Because our products are based on an engineered humanized surfactant, they can be produced economically at scale, as a high quality pharmaceutical, without the risk of potential transmission of animal-borne diseases or adverse immunological reaction. Products from our technology platform have the potential to be superior to currently marketed surfactants, treat critical care respiratory conditions, and treat larger, ambulatory patient populations that could benefit from surfactant therapy or drug delivery.

**Recent Publications by Discovery Laboratories:**



- [Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters.](#)  
*Neutrophil elastase (NE) has been recognized as a double-edge sword as it...*23rd May, 2009  
Minase Research Institute, Discovery Laboratories II, Ono Pharmaceutical- Pulm Pharmacol Ther. 2008 Dec;21(6):884-91. Epub 2008 Oct 17. ([DOI Direct Link](#))
- [Evaluation of the searching abilities of HBOP and HBSITE for binding pocket detection.](#)  
*We evaluated the pocket-searching abilities of the computer programs HBOP...*29th April, 2009  
Discovery Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama- J Comput Chem. 2009 Dec;30(16):2728-37. ([DOI Direct Link](#))
- [Optimizing the neonatal thermal environment.](#)  
*Devices used to maintain thermal stability in preterm infants have...*29th September, 2006  
Discovery Laboratories, Inc, Warrington, Pennsylvania, USA.- Neonatal Netw. 2006 Jul-Aug;25(4):251-60.
- [Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes.](#)  
*Here, the comparisons of performance of nine consensus scoring strategies,...*15th April, 2006  
Discovery Laboratories, Toyama Chemical Co., Ltd., Japan.- J Chem Inf Model. 2006 Jan-Feb;46(1):380-91. ([DOI Direct Link](#))
- [Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model.](#)  
*We designed and synthesized small-molecule activator protein-1 (AP-1)...*17th February, 2006  
Discovery Laboratories, Toyama Chemical Co., Ltd., 4-1 Shimookui 2-chome,- J Med Chem. 2006 Jan 12;49(1):80-91. ([DOI Direct Link](#))
- [New AMBER force field parameters of heme iron for cytochrome P450s determined by quantum chemical calculations of simplified models.](#)  
*The heme protein, cytochrome P450, is an oxidoreductase that plays an...*9th June, 2005  
Discovery Laboratories, Toyama Chemical Co, Ltd, 2-4-1 Shimookui, Toyama- J Comput Chem. 2005 Jun;26(8):818-26. ([DOI Direct Link](#))
- [Studies of binding modes of \(S\)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking.](#)  
*PURPOSE: This study investigated the structural features of CYP2C19...*11th May, 2005  
Discovery Laboratories, Toyama Chemical Co Ltd, 2-4-1 Shimookui, Toyama- Pharm Res. 2004 Dec;21(12):2270-8.
- [YM-92447 \(spinosulfate A\), a neuraminidase inhibitor produced by an unidentified pycnidial fungus.](#)  
*The heme protein, cytochrome P450, is an oxidoreductase that plays an...*31st March, 2005  
Lead Discovery Laboratories, Institute for Drug Discovery Research,- J Antibiot (Tokyo). 2004 Dec;57(12):812-5.
- [Design, synthesis, and biological evaluation of new cyclic disulfide decapeptides that inhibit the binding of AP-1 to DNA.](#)  
*The transcription factor activator protein-1 (AP-1) is an attractive...*31st August, 2004  
Discovery Laboratories, Toyama Chemical Co., Ltd., 4-1 Shimookui 2-chome,- J Med Chem. 2004 Aug 12;47(17):4239-46. ([DOI Direct Link](#))
- [Studies on novel bacterial translocase I inhibitors, A-500359s. III. Deaminocaprolactam derivatives of capuramycin: A-500359 E, F, H; M-1 and M-2.](#)  
*Novel derivatives of capuramycin were obtained when 10 mM of...*20th June, 2003  
Lead Discovery Laboratories, Sankyo Co., Ltd., 1-2-58 Hiromachi,- J Antibiot (Tokyo). 2003 Mar;56(3):259-67.

**Press Releases on Discovery Laboratories:**

<a href="#">Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards</a>	23rd November, 2009	Amgen	THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate <sup>®</sup> (romiplostim)
<a href="#">Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman</a>	23rd November, 2009	Ligon Discovery, Inc.	CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment
<a href="#">Reportlinker Adds Hand Sanitizers - US Market Trends</a>	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Hand Sanitizers - US Market Trends <a href="http://www.reportlinker.com/p0164260">http://www.reportlinker.com/p0164260</a>
<a href="#">Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients</a>	23rd November, 2009	Proteon Therapeutics, Inc.	WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing
<a href="#">Four Senior Executives Join Orexigen(R) Therapeutics Management Team</a>	23rd November, 2009	Orexigen Therapeutics, Inc.	SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen <sup>®</sup> Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management

## BioNews Results for Discovery Laboratories



- [BUYINS.NET: Discovery Laboratories \(DSCO\) Daily Short Sale Trading Volume Through 11-17-09. Over 56 Million Shares Shorted in Past 3 Months.](#)  
*Individual.com: Nov 20 2009 8:41AM Matching: discovery laboratories*
- [Ligon Discovery Nets \\$1M Investment](#)  
*GenomeWeb: Nov 20 2009 7:50AM Matching: discovery laboratories*
- [Global Market Perspective Review on JRCC, HLCS, ISPH, CHIP, GENZ and DSCO From TheFortuneFinancial.com](#)  
*TradingMarkets: Nov 19 2009 12:07PM Matching: discovery laboratories*
- [Global Market Perspective Review on JRCC, HLCS, ISPH, CHIP, GENZ and DSCO From TheFortuneFinancial.com](#)  
*Yahoo! Canada: Nov 19 2009 11:58AM Matching: discovery laboratories*
- [Research and Markets: Drug Discovery Technologies - A Global Update of Market Trends & Opportunities](#)

- SmartBrief: Nov 19 2009 2:58AM Matching: discovery laboratories*
- [Global Market Perspective Review on JRCC, HLCS, ISPH, CHIP, GENZ and DSCO From TheFortuneFinancial.com](#)
- NewsBlaze: Nov 19 2009 11:56AM Matching: discovery laboratories*
- [Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA](#)
- Pharmacy Choice: Nov 18 2009 4:38AM Matching: discovery laboratories*
- [Discovery Labs submits trial design for Surfaxin to FDA](#)
- SmartBrief: Nov 18 2009 8:28PM Matching: discovery laboratories*
- [Research and Markets: Drug Discovery Technologies - A Global Update of Market Trends & Opportunities](#)
- Forbes.com: Nov 18 2009 3:32PM Matching: discovery laboratories*
- [Research and Markets: Drug Discovery Technologies - A Global Update of Market Trends & Opportunities](#)
- Business Wire UK: Nov 18 2009 3:12PM Matching: discovery laboratories*
- [Discovery Laboratories \(DSCO\) Submits Proposed Protocol for Surfaxin Clinical to U.S. FDA](#)
- Street Insider: Nov 17 2009 12:33PM Matching: discovery laboratories*
- [Discovery Labs Submits Proposed Protocol for Surfaxin Trial](#)
- FDA News: Nov 17 2009 11:29PM Matching: discovery laboratories*
- [Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA](#)
- Interest!ALERT: Nov 17 2009 3:12PM Matching: discovery laboratories*
- [Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA](#)
- NewsBlaze: Nov 17 2009 12:30PM Matching: discovery laboratories*
- [Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA](#)
- Pharma Live: Nov 17 2009 1:20PM Matching: discovery laboratories*

#### Discovery Laboratories Clinical Trials:



- [Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old](#)

#### Discovery Laboratories Patents:



- 7582312- [Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof](#)
- 7541331- [Surfactant treatment regimen](#)
- 5962523- [Methods of using butyric acid derivatives to protect against hair loss](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

